Full Press Release Details
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.
SGMT
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
Key Takeaway: FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models